SMMT vs TISCY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SMMT · Summit Therapeutics$16.33 ▲ 15.08%
TISCY · TAISEI CORP UNSP ADR EACH REP 0.25 ORD SHS$16.74 ▼ 3.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SMMT -10.8%
- TISCY -5.1%
Head to head
| Metric | SMMT | TISCY |
|---|---|---|
| Price | $16.33 | $16.74 |
| Change today | ▲ 15.08% | ▼ 3.18% |
| Market cap | $13.06B | $13.05B |
| Return, 3 months | +9.8% | -18.8% |
| Return, year to date | -6.6% | -26.3% |
| Return, 1 year | -10.2% | -5.1% |
| P/E (TTM) | – | 10.1 |
| P/B | 23.1 | 1.8 |
| P/E percentile vs own 5y | 26th | – |
| Dividend yield | – | 2.90% |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | +61.9% | – |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -192.5% | – |
| Analyst target vs. price | +81.8% | – |
| Analyst buy share | 62% | – |
| RSI (14) | 53 | 44 |
| 30-day volatility | 86.2% | 107.0% |
| Max drawdown, 1 year | -52.9% | -51.2% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | – |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SMMT is the largest of the group by market value.
- TISCY has returned the most over the past year.
- SMMT has been the calmest stock over the last 30 days.